Due to the profound effect of novel coronavirus disease 2019 (COVID-19) on healthcare systems, surgical programs across the country have paused surgical operations and have been utilizing virtual visits to help maintain public safety. For those…
Objective: To identify the frequency of insurance related issues with intravenous immunoglobulin (IVIg) therapy approval for patients with autoimmune gastrointestinal dysmotility (AGID) and the outcomes of missed IVIg treatments.
